Shopping Cart 0
Cart Subtotal
USD 0

MedImmune LLC - Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

MedImmune LLC-Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-GlobalData's summarization of the company's business strategy.

- SWOT analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list of key locations and subsidiaries of the company, including contact details.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

Highlights

MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture, and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other next-generation molecules targeting various diseases. MedImmune undertakes research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases. It also develops vaccines for the prevention of infectious diseases. The company operates three R&D centers in Gaithersburg, Maryland; Cambridge, the UK; and Mountain View, California. MedImmune is headquartered in Gaithersburg, Maryland, the US.

MedImmune LLC Key Recent Developments

Feb 14,2019 MedImmune brand to be retired as biologics integrate into AstraZeneca's new R&D structure

Dec 04,2018 CELLINK announces collaboration with MedImmune to utilize CELLINKs' 3D-Bioprinting technology for drug discovery

Sep 14,2018 US FDA Approves LUMOXITI (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia[Newswire : Healthcare-BW]

Aug 20,2018 AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

Jun 18,2018 N4 Pharma: Update on Nuvec

Reasons to buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

- Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

- Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

MedImmune LLC-Key Facts

MedImmune LLC-Key Employees

MedImmune LLC-Key Employee Biographies

MedImmune LLC-Major Products and Services

MedImmune LLC-History

MedImmune LLC-Company Statement

MedImmune LLC-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

MedImmune LLC-Business Description

MedImmune LLC-SWOT Analysis

SWOT Analysis-Overview

MedImmune LLC-Strengths

MedImmune LLC-Weaknesses

MedImmune LLC-Opportunities

MedImmune LLC-Threats

MedImmune LLC-Key Competitors

Section 3-Company's Lifesciences Financial Deals and Alliances

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

MedImmune LLC, Recent Deals Summary

Section 4-Company's Recent Developments

Feb 14, 2019: MedImmune brand to be retired as biologics integrate into AstraZeneca's new R&D structure

Dec 04, 2018: CELLINK announces collaboration with MedImmune to utilize CELLINKs' 3D-Bioprinting technology for drug discovery

Sep 14, 2018: US FDA Approves LUMOXITI (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia[Newswire : Healthcare-BW]

Aug 20, 2018: AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

Jun 18, 2018: N4 Pharma: Update on Nuvec

Apr 04, 2018: AstraZeneca's early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC

Feb 28, 2018: MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics

Jan 01, 2018: New Bio-Incubator and Life-Science Accelerator Capability Launches at the Babraham Research Campus

Section 5-Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

MedImmune LLC, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

MedImmune LLC, Key Facts

MedImmune LLC, Key Employees

MedImmune LLC, Key Employee Biographies

MedImmune LLC, Major Products and Services

MedImmune LLC, History

MedImmune LLC, Other Locations

MedImmune LLC, Subsidiaries

MedImmune LLC, Key Competitors

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

MedImmune LLC, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

MedImmune LLC, Recent Deals Summary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

bioCSL Inc

ID Biomedical Corporation

Sernova Corp

Novartis Vaccines and Diagnostics Inc

GlaxoSmithKline Plc

Variation Biotechnologies Inc

Eli Lilly and Co

Pfizer Vaccines LLC

Genentech Inc

Novartis AG

Incyte Corp